<DOC>
	<DOCNO>NCT01447576</DOCNO>
	<brief_summary>The purpose study ass long-term safety , tolerability efficacy oral OPC-34712 adjunctive therapy treatment adult patient Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>Study Safety &amp; Tolerability OPC-34712 Adjunctive Therapy Treatment Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male female subject 18 65 year age , diagnosis single recurrent , nonpsychotic episode major depressive disorder , define DSMIVTR criterion confirm Mini International Neuropsychiatric Interview ( M.I.N.I . ) equal great 8 week duration . Subjects must currently take allowable antidepressant therapy adequate dose minimum six week end screen period ( ie time Baseline visit ) . Subjects must report history current depressive episode inadequate response least one four adequate antidepressant treatment . Females breastfeed and/or positive pregnancy test result prior receive study drug . Subjects report inadequate response three adequate trial antidepressant treatment current depressive episode therapeutic dose adequate duration . Subjects current Axis I ( DSMIVTR ) diagnosis : Delirium , dementia , amnestic cognitive disorder Schizophrenia , schizoaffective disorder , psychotic disorder Bipolar I II disorder , eat disorder ( include anorexia nervosa bulimia ) , obsessive compulsive disorder , panic disorder , posttraumatic stress disorder . Subjects clinically significant current Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>